Expressive Writing Therapy for Cancer Survivors
Trial Summary
What is the purpose of this trial?
The Chinese American Cancer Survivors Writing Study is a Randomized Controlled Trial (RCT) testing the feasibility and efficacy of the Expressive Helping (EH) intervention among Chinese American cancer survivors.
Will I have to stop taking my current medications?
The trial protocol does not specify whether you need to stop taking your current medications. It seems likely that you can continue your medications, especially since the trial includes those still on medication for managing cancer-related symptoms.
What data supports the effectiveness of the treatment Expressive Writing Therapy for Cancer Survivors?
Is expressive writing therapy safe for cancer survivors?
How is the Expressive Helping treatment different from other treatments for cancer survivors?
Expressive Helping is unique because it involves writing about personal traumatic experiences to improve mental and physical health, unlike other treatments that may focus solely on medical or physical interventions. It combines emotionally expressive writing with peer support, offering a psychological approach to enhance quality of life and self-care in cancer survivors.12349
Eligibility Criteria
This trial is for Chinese American cancer survivors over 18 who prefer Mandarin or Cantonese and can read/write in Chinese. They should be within 5 years of completing treatment for stage I-III cancer. Those with writing difficulties or active in support groups more than once a week cannot join.Inclusion Criteria
Exclusion Criteria
Timeline
Screening
Participants are screened for eligibility to participate in the trial
Treatment
Participants engage in writing sessions, including expressive and factual writing, over four weeks
Follow-up
Participants are monitored for psychological symptoms and quality of life at multiple intervals post-intervention
Treatment Details
Interventions
- Expressive Helping
- Expressive Writing
- Factual Writing
Find a Clinic Near You
Who Is Running the Clinical Trial?
New York University
Lead Sponsor
National Institute on Minority Health and Health Disparities (NIMHD)
Collaborator